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Abstract
Background: Hepatitis B and C are silent killers not yet recognized as major public health challenges in many
developing countries with huge disease burden. In Ethiopia, Hepatitis B is endemic with an average prevalence of
10.8 %, and the prevalence of Hepatitis C is 2 %. The prevalence of both infections, however, is likely to be underreported
due to the lack of diagnostic facilities and appropriate surveillance systems. Ethiopia is also among the many Sub-Sahara
African countries lacking a coordinated and systematic national response to chronic viral hepatitis.
The objective of this study is to examine the current level of response to viral Hepatitis B & C in Ethiopia with the aim
to bring identified gaps to the attention of relevant stakeholders and policy makers.
Methods: This cross-sectional qualitative study was based on semi-structured in-depth interviews with 21 key
informants from health facilities, health offices, pharmaceutical companies, regulatory bodies, professional
association and blood bank units. Participants were selected purposively based on their role in the national
hepatitis response. The investigators also reviewed available policy and strategy documents, standards of
practice and surveys, and paid visits to pharmaceutical premises to check the availability of antiviral drugs.
Thematic analysis was employed to make sense of the data. During the data analysis process, all the authors
critically read the materials, and data was triangulated by source, interpreter view and thematic perspective to
ensure accurate representation and comprehensiveness, and validation of the interviewees’ responses. Once
each investigator reviewed the data independently, the team reached a common understanding of the scope
and contexts of the information attained. Data were subsequently reduced to key concepts, and case stories
were taken with successive revisions. The key concepts were later coded into most basic meaningful categories. The
World Health Organization (WHO) global hepatitis response framework was used to organize the analysis.
Results: Ethiopia is in the process of preparing strategic plan and guidelines for viral hepatitis. However, the country
still lacks the required partnerships, and resource mobilization as a national health response is limited. Community
awareness on the disease transmission and its sequel is poor. Viral hepatitis screening services are not widely available
except for the occasional mandatory medical checkups for work or travel purposes. Healthcare providers often take no
further action after diagnosing patients with viral hepatitis due to lack of treatment guidelines and strategic
frameworks for screening, diagnosis, and treatment. Besides, drugs that are effective in the treatment of viral
hepatitis are not available, mainly due to regulatory challenges.
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Conclusions: Viral hepatitis and its disease burden are getting little attention in Ethiopia and many low-income
countries. The levels of technical guidance and financial support from the international community are low. To date,
the response to the infections in Ethiopia is patchy. Thus, the country needs to formulate policy and strategies in the
areas of disease surveillance, risk group identification and screening, use of the birth dose of hepatitis B vaccine, and
care and treatment. Improving availability of data on viral hepatitis, access to low-cost generic drugs and developing
and dissemination of treatment guidelines are also critical. Leveraging the successful Health Extension Program
for a hepatitis response, and exploring ways to learn from and integrate into the HIV/AIDS program should also
be considered.
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Background
The hepatitis B and C viruses cause chronic viral hepatitis,
a major global health problem responsible for 57 % of liver
cirrhosis [1] and 75 % of primary liver cancer [2] cases, re-
spectively. Around 2.2 billion people (over a third of the
world population) worldwide have evidence of past or
present infection with the viruses, and around 500 million
of these are chronically infected, more than ten times
those affected by HIV/AIDS [3]. Each year, chronic viral
hepatitis results in around 1.3 million deaths from chronic
liver disease and hepatocellular carcinoma (HCC) [4]. This
death toll is comparable with the 1.5 million deaths caused
by HIV and 1.2 million deaths resulting from either tuber-
culosis or malaria each year [5].
Hepatitis B is responsible for the chronic infection of
240–350 million people each year. Around 780,000 of
these die of either cirrhosis or liver cancer [6, 7]. Simi-
larly, Hepatitis C infects 170 million people each year
and causes chronic infection and death in 130–150 million
and 350–500,000, respectively [8].
Hepatitis B virus is endemic in Africa next to Asia,
with a seroprevalence rate of between 8 and 20 % [6].
West Africa is particularly affected, with 95 % of the adult
population showing indicators of previous hepatitis B virus
infection while the regional hepatitis C prevalence is lower
than hepatitis B at 5.3 % of the general population. The
world’s highest prevalence is in Egypt (17.5 %), followed by
Cameroon (13.8 %) and Burundi (11.3 %) [9]. Africa also
has the highest hepatocellular carcinoma incidence rate in
the world, partly due to a 5–25 % co-infection rate with
HIV [10], which accelerates the progression to cirrhosis
and hepatocellular carcinoma [11, 12].
In Ethiopia, there is a lack of nationwide representative
data on hepatitis B and hepatitis C infections. It is, there-
fore, difficult to present the incidence, prevalence, and
mortality rates accurately. A national survey conducted
several years ago, and regional estimates have shown wide
geographic and socioeconomic variation in hepatitis B
prevalence, ranging between 5.7 and 10.8 % [13–15]. The
incidence is higher in males with an evidence of past infec-
tion marker (HbcAb) seen in 50 % by 20 years of age, and
70 % at the age of 49 [16]. The seroprevalence of HbsAg is
found to be as high as 14.4 % in blood donors [17]. Earlier
hospital-based studies showed that hepatitis B accounts
for 12 % of hospital admissions and 31 % of deaths in Ethi-
opian hospitals [18]. Studies also found that at least one of
the hepatitis markers was found in 78 % of patients with
hepatocellular carcinoma, 86 % of chronic hepatitis cases,
and 88 % of cirrhosis patients in Ethiopia [19].
In Ethiopia, the overall seroprevalence of hepatitis C is
estimated to be around 2 %, and infection is most com-
monly associated with contaminated medical instruments
[20]. A recent study from northern Ethiopia showed the
prevalence of hepatitis C to be three-fold among HIV-
infected individuals [21]. There are no studies from the
country on other high-risk groups such as drug injectors,
prisoners, and homosexuals. In general, hepatitis B and C
infections are responsible for the majority of cases of he-
patocellular carcinoma and liver cirrhosis in Ethiopia [1].
However, despite the higher rate of progression to chronic
complications with hepatitis C, hepatitis B is more signifi-
cant due to the high prevalence [22].
In Africa and Asia, hepatitis B is often caused by pre-
natal transmission from mother to child or household
transmission from a close contact during early childhood.
In these settings, hepatitis C is commonly transmitted by
sharing needles for drug use, needlestick injury, improper
sterilization of medical equipment and transfusion of in-
adequately screened blood [23]. The clinical manifesta-
tions of both infections depend on the age of the patient,
immune status, and disease stage. Similar to HIV, the long
“symptom-free” period, which characterizes both infec-
tions, contributes to their spread. The risk of chronicity of
hepatitis B is inversely proportional to the age at which
the infection is acquired. Perinatal and early neonatal in-
fections have a chronicity of 90 % while the rate for infec-
tions acquired during the first 5 years of life drops to 60 to
20 %. The rates drop to as low as 5 % for infections occur-
ring during adulthood [24, 25].
Overall, hepatitis B infection accounts for 30 % of cirrho-
sis and 45 % of hepatocellular carcinoma [5, 26]. Hepatitis
C has a higher chronic asymptomatic rate of 55–85 %, with
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15–30 % developing liver cirrhosis within 20 years. The
risk of hepatocellular carcinoma in persons with cirrhosis
is approximately 2–4 % yearly [27]. Hepatocellular carcin-
oma accounts for around 25 % of liver cancer worldwide
[28]. In Ethiopia, the mortality rate reported due to hepato-
cellular carcinoma is among the highest in the world at
around 93.45 per 100,000 [27].
Given the magnitude and seriousness of the problem,
many agree that prevention and control of viral hepatitis
need a high degree of attention similar to HIV, TB, and
Malaria by all stakeholders, including governments and
funding agencies. And there have been calls by various
agencies, associations and groups for an organized global
response with well-articulated policies and strategies to
address this largely forgotten problem. The World Health
Organization has proposed a comprehensive approach by
outlining four strategic axes to guide viral hepatitis re-
sponse in member countries. In this study, we used this
framework to examine the existing level of response in
Ethiopia. The objective is to review the policy environ-
ment, strategy and implementation and regulation of
hepatitis B & C prevention, care, and treatment activities




In this cross-sectional qualitative study, key-informant
interviews were used to obtain data directly or indirectly
on policy, strategy and service delivery for viral hepatitis
in Ethiopia. The information is primarily collected from
participants who are considered the main stakeholders
of the multisectoral national viral hepatitis response.
Separate semi-structured interview guides were used for
each group of respondents. Interview data was supple-
mented with a review of available policy and strategy
documents as well as surveys and standards of practice.
In addition, the investigators paid visits to pharmaceut-
ical premises to check the availability of antiviral drugs
used for the treatment of viral hepatitis. Data collection
was conducted between December 2014 and January
2015 by two of the authors using semi-structured inter-
view guides. Participants were asked open-ended ques-
tions. The interviews lasted an average of twenty minutes
and recorded as handwritten notes.
Sampling & data collection strategy
The investigators interviewed diverse groups of respon-
dents, including policymakers, health care providers, pa-
tients, regulatory body officials, national and regional
blood bank unit staff, laboratory technologists, pharmacists
and staff from public and private pharmaceutical suppliers.
The informants are categorized into six groups, with each
group containing one to three respondents. In total, 21
people were interviewed as shown in Table 1. The
first group represented staff from the Federal Ministry
of Health (FMOH) and Drug Administration and
Control Authority, who are responsible for policy for-
mulation and strategy development. They provided in-
sights on current policies and strategies regarding
viral hepatitis prevention, care, and treatment. The spe-
cific issues addressed included availability and registration
of antivirals for hepatitis treatment on essential drug list
and matters related to treatment protocols for viral hepa-
titis. The information obtained from these was further
substantiated through an interview with a committee
member of Ethiopian Gastroenterological Association.
The second group represented clinical practitioners who
are responsible for diagnosing, treating and care of pa-
tients with viral hepatitis. The clinicians were recruited
from Gastroenterology specialty centers in Addis Ababa,
from a tertiary referral hospital in the capital and private
clinics. Ethiopia is a country with more than 90 million
people. However, it has a limited number of gastroenterol-
ogists and specialty services. For instance, the number of
Table 1 National policy, strategy, guidelines and survey
documents
1. Health Sector Development Program IV 2010/11 – 2014/15,
Federal Ministry of Health Ethiopia(FMOH)
2. Ethiopia National Expanded Program on Immunization,
comprehensive multi-year plan 2011–15 (FMOH-Ethiopia).
3. Ethiopian National health care quality 2016–20, FMOH-Ethiopia
4. National Essential Medicine List Fifth Edition, Food, Medicine
and Healthcare Administration and Control Authority of Ethiopia
(FMHACA).
5. National blood transfusion services strategy, Federal Ministry of
Health Ethiopia(FMOH) February, 2005,
6. Ethiopia Global Health Initiative Strategy, The U.S. Ethiopia GHI
Team, v. 4, December 22, 2010.
7. WHO-Ethiopia country cooperative strategy 2012–2015.
Guidelines
1. Standard treatment guidelines for primary hospitals, January
2010, Food, Medicine and Healthcare Administration and Control
Authority of Ethiopia (FMHACA)
2. Standard Treatment Guidelines for General Hospital, 3rd edition,
2014, Food, Medicine and Healthcare Administration and Control
Authority of Ethiopia (FMHACA).
3. Standard Treatment Guidelines For health centers, 2nd edition,
2014, Food, Medicine and Healthcare Administration and Control
Authority of Ethiopia (FMHACA).
4. Infection prevention guideline for health care facilities in Ethiopia,
July, 2004 Federal Ministry of Health Ethiopia(FMOH)
Surveys
1. Ethiopian National Hepatitis B Study. Kefene H1, Rapicetta M, Rossi
GB, Bisanti L, Bekura D, Morace G, Palladino P, Di Rienzo A, Conti S,
Bassani F, et al. J Med Virol. 1988 Jan;24(1):75–84.
2. Evaluation of injection safety & health care waste management in
Ethiopia, 2009 survey report, USAID, Ethiopia
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gastroenterologists in 2008 was only ten. Although the num-
ber of Gastroenterologists rose to 20 by 2015, it remains low
for such a huge population. Besides, the number of senior
gastroenterology consultants is very few, and their services
are limited to the capital. Furthermore, there are only two
Food, Medicine, and Health Care Administration and
Control Authority (FMHACA) registered gastroenterology
specialty private clinics in the country. Two of the senior
gastroenterology consultants, including one working in
FMHACA registered clinic, were purposefully selected for
the interview due to their long experience, the fact that they
see most of the referred cases and their knowledge of the
trends in viral hepatitis epidemiology and diagnosis and
treatment services in the country. The other clinical practi-
tioners, an internist and general medical practitioners se-
lected from public and private hospitals were asked
questions regarding the tools they have and the challenges
they face during screening, diagnosis, treatment and care of
patients with viral hepatitis. The specific issues discussed in-
clude the availability of diagnostic facilities, treatment proto-
cols, and drugs, and patient satisfaction.
The third group of interviewees were pharmacists from
private and government-owned institutions. The pharma-
cists were asked about their knowledge and experiences with
drug treatment for viral hepatitis, the rules and regulations
on the handling of antiviral drugs, and the availability of
medicines in the pharmaceutical market. The fourth group
represents patients with chronic hepatitis, selected randomly
from government and private-owned institutions in Addis
Ababa. Emphasis was given to their real experiences regard-
ing their diagnosis and treatment. They were also asked
about their awareness of viral hepatitis before and after diag-
nosis, and the availability and affordability of the services.
The fifth group represented lab technologists from national
and regional blood bank units and general laboratory ser-
vices. These participants were interviewed about laboratory
aspects, including the screening protocol for hepatitis B and
C infections. The last group are informants from pharma-
ceutical importing companies who gave insights on chal-
lenges associated with the rules and regulations surrounding
the importing and distribution of hepatitis B vaccine and an-
tivirals for the treatment of viral hepatitis.
In addition to the interviews, the available policy, strat-
egy, survey and standard of practice documents were col-
lected by interviewers in hard and soft copy formats
during each institutional visit for the interviews. Add-
itional materials were gathered through cross-referencing
from the Internet (Table 1). Furthermore, the investigators
made on-site check-up visits at four governments and six
private pharmacies to check the availability of antiviral
drugs used in the treatment of viral hepatitis.
Data analysis
Thematic analysis [29] was used to make sense of the data.
Interview notes and the strategic documents collected
were thoroughly reviewed for themes relevant to the viral
hepatitis response in Ethiopia. During the data analysis
process, all the authors critically read the materials, and
data was triangulated by source, interpreter view and the-
matic perspective to ensure accurate representation and
comprehensiveness and validation of the interviewees’ re-
sponses. Once each investigator reviewed the data inde-
pendently, the team reached a common understanding of
the scope and contexts of the information attained. Data
were subsequently reduced to key concepts, and case stor-
ies were taken with successive revisions. The key concepts
were later coded into most basic meaningful categories.
Through this process, 32 key concepts were coded, and
the information gathered from participants, document re-
views, and observation was categorized under the WHO’s
four-axes global hepatitis response framework shown in
Table 2 to help highlight the gaps in the health system.
Table 2 Thematic analysis framework and Interview matrix
AXIS I Raising awareness, promoting partnerships & mobilizing resources AXIS II Evidence-based policy & data for action
Interview with policymakersa
Interview with gastroenterological associationb
Interview with clientse
Interview with policymakersa
Interview with gastroenterological associationb
AXIS III Prevention of transmission AXIS IV Screening, care & treatment
Interview with policymakersa
Interview with laboratory technologistsf
Interview with health care professionalsc
Interview with pharmacistsd
Interview with pharmaceutical suppliersg
Interview with clientse
In all four axes available national policy, strategy and research documents reviewed
Note
aOne from Federal Ministry of Health Disease prevention and control & one from Ethiopian Food, Medicine and Health administration and control Authority
bExecutive member of Gastroenterologists association
cTwo gastroenterologists, one internist and one General Practitioner from government and private health institutions
dTwo participants from government and two from private pharmacies
eTwo patients from government hospitals and two from private hospitals
fFour informants: Two from national and regional blood bank units and two from general lab units representing public and private sectors
gTwo individuals from pharmaceutical suppliers interviewed
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The interview questionnaires were reviewed by “Adera
Gastroenterology Clinic” ethics committee and a waiver
was given. Verbal consent was obtained from each inter-
viewee before interviews commenced. Participants were
assured anonymity and confidentiality of their responses.
Results and discussions
Table 3 provides a summary of coded responses from the
interviews for each of the six key informant groups along
the four axes. Details of the findings are organized in a
similar manner and discussed in the subsequent sections.
Raising awareness, promoting partnerships, and mobilizing
resources
Community awareness, beliefs, and taboos
One of the interviewees was a 60-year-old man who re-
ported being healthy until experiencing progressive weak-
ness and fatigue over the previous 2 years. He said he had
Table 3 Summary of interview data per informant group
AXES Informant group Coded responses
AXIS I Policy makers & Gastroenterology
Association informant




• No implementing & donor agencies
• No organizing body
• Minimal media awareness initiatives
Patients • Traditional beliefs
• No awareness about the disease & transmission
• Awareness obtained via incidental diagnosis of oneself or close relative
AXIS II Policy makers & Gastroenterology
Association informant
• No policy & strategy for prevention, care & treatment
Evidence-based policy & data
for action
• No current national survey on both hepatitis B & C
• No hepatitis surveillance system
• No antivirals for hepatitis treatment registered on essential drug list
AXIS III Policymakers • Hepatitis B vaccine as pentavalent vaccine in Expanded Program on
Immunization(EPI)
Prevention of transmission • 24-h-Birth-dose of hepatitis B vaccine not available
• No Adult Hepatitis B catch-up vaccine administration policy
• No Hepatitis specific health promotion or health education strategy
• HIV prevention activity indirectly helps in control of viral hepatitis
Laboratory technologists • Standard of Practice to screen HIV, Hepatitis, & C, and Syphilis in blood
banks
• Hepatitis screening only in private institutions upon request
AXIS IV Healthcare professionals • Hepatitis screening only in private institutions upon request
Screening, care & treatment • No organized treatment facility in the country
• Smuggled hepatitis treatment drugs are not affordable
• Lab investigation for treatment follow-up done abroad through agents,
and is neither affordable nor accessible to the majority
• Patients neglected & discriminated
• Getting treatment is a human right issue
Pharmacists • Antivirals for hepatitis treatment not available on market
• Antivirals for hepatitis treatment not registered on essential drug list
Drug suppliers • No legal support to import antivirals for hepatitis and HIV
• Case-based drug import by prescription is very expensive
• No awareness as a major health problem
Clients • No awareness about hepatitis screening
• Prescribed drugs not available on market
• Smuggled hepatitis treatment drugs are not affordable
• Feeling of discrimination
Client case stories • four case stories narrated
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hepatitis B and never heard of the silent course and ser-
iousness the infection until he received the diagnosis. The
experience of the other patients we interviewed was also
similar with incidental diagnosis and a lack of knowledge
on how they acquired it and the consequences.
The trade-off in viral hepatitis is the long duration of in-
fection and complications. It often has a symptom-free
clinical course which misleads around two-thirds of car-
riers not to seek medical care [30]. In Ethiopia, viral hepa-
titis is commonly known as “Yewef Beshita” in the widely
spoken Amharic language, which means a disease from a
bird, with the bird frequently associated being a bat. There
is a widespread belief that if a bat flies around someone
and drops its urine, a person gets liver disease, which
manifests as a yellowish discoloration of the eyes and
yellow-colored urine. The community does not under-
stand viral hepatitis as a disease with asymptomatic stage
or a carrier state. Those who have “Yewef Beshita” are
traditionally advised to take bed rest, eat sweets, and go to
a traditional healer for herbal medicine. It is generally con-
sidered as an illness with no modern treatment. This lack
of awareness clearly puts the communities at risk. Hence,
new hepatitis infections must be reduced as a priority by
raising community awareness and providing access to ap-
propriate and culturally acceptable information about the
mode of transmission, its consequences, and currently
available care and treatment to protect themselves, their
families and others.
According to a participant from Ethiopian gastro-
enterological association, efforts are being made by the
organization to improve community awareness. The in-
terventions reported were broadcasting key messages on
viral hepatitis through local radios and organizing world
hepatitis day celebrations every year. The informant be-
lieved these efforts had contributed to raising commu-
nity awareness and sensitizing policy makers to harness
progressive policies and strategies. However, improving
community awareness on viral hepatitis requires a well-
defined and sustainable strategy with education given in
school curricula, health facilities, and through regular
campaigns to address existing knowledge gap and mis-
conceptions. Given the similarity of hepatitis B and C in-
fections with HIV, the possibility of addressing the issues
during the HIV-related awareness raising efforts should
be considered. In rural Ethiopia, community conversa-
tions contributed to successes in the national HIV/AIDS
response by improving HIV testing uptake, patient sup-
port and treatment adherence [31]. Therefore, the au-
thors believe that this might be a good lesson to
replicate for viral hepatitis on awareness creation, com-
munity mobilization for changing risk behaviors and
identifying vulnerable at-risk groups.
This study did not address the level of awareness
among health workers in Ethiopia. Our literature review
did not yield any studies comprehensively addressing the
issue either. However, there is evidence that at least
some precautions related to the prevention and control
of viral hepatitis are not well-practiced by health
workers in the country [32]. Conducting in-depth stud-
ies, and addressing the gaps through appropriate pre-
service and in-service training would, therefore, be cru-
cial for health workers. This will help health workers
equip themselves with the necessary knowledge and
skills to provide integrated prevention, care, and treat-
ment services for patients and protect themselves from
the infections through precautions and vaccination.
Promoting partnerships & mobilizing resources
According to the informant from the disease control
unit of the FMOH, the organization had been working
with local partners like the Ethiopian Gastroentero-
logical Association, with which it had collaborated since
its establishment in 2008. The association took part in
capacity building, training, and advising, and had been
active in the provision of current viral hepatitis messages
and interviews to the media. The association's informant
also reiterated the fact that the organization was instru-
mental in establishing the Ethiopian Liver Health Asso-
ciation (ELHA) and setting a global hepatitis network
via the World Hepatitis Alliance. Besides, the participant
from the ministry stated that the WHO country office
had been actively working alongside the ministry in vari-
ous areas that have a direct impact on prevention of
hepatitis B and C infections. Areas of collaboration in-
clude blood safety and supply of vaccines for the ex-
panded program on immunization.
Hepatitis B virus is a hundred times more infectious
than HIV [33], and ten times more people have HBV in-
fections [3]. Despite this, however, the global community
paid much less attention to viral hepatitis. For instance,
the budget allocated to it by WHO is 70 and 30 times
less than that of TB and HIV, respectively [26]. In the re-
cent past, we have witnessed a global coalition able to
gather vast funding and policy attention on HIV, TB and
malaria. This had contributed to a marked decline in
deaths from these diseases over the last 13 years and
helped Ethiopia and other resource-limited countries
achieve the sixth Millennium Development Goal (MDG
6). Viable global partnerships with an integrated health
system strengthening approach are vital for low-income
countries like Ethiopia in responding to the multiple
public health challenges they face. According to the par-
ticipant from FMOH, however, no developmental agency
was working in Ethiopia in the area of viral hepatitis pre-
vention, care or treatment. Even the President's Emer-
gency Plan for AIDS Relief (PEPFAR) addressed only
those co-infected with HIV.
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One of the most important partnerships would be
working with leading organizations like WHO as it pro-
vides technical guidance in conducting a situational ana-
lysis and adapting strategies and guidelines to the
country context. Ethiopia missed two opportunities to
collaborate with WHO on viral hepatitis: the 2012 global
baseline survey [34], and the civil-society survey [35].
Participation in these surveys would have provided valu-
able information for relevant policy formulation and de-
signing strategies and programs.
Evidence-based policy and data for action
Interview with policy makers from FMOH revealed that
they recognized viral hepatitis as a public health agenda
for a long time. However, the response had been slow
due to “competing priorities, lack of budget and a lack of
partners providing support and guidance for the re-
sponse.” Currently, the ministry organized a national task
force and started working on the development of stra-
tegic documents and treatment guidelines following the
global momentum and international resolutions.
Despite the burden of viral hepatitis and the challenge
it poses, chronic hepatitis was only recently fully ac-
knowledged globally as a health problem. In 2010, the
World Health Assembly declared its first resolution
(WHA63:18) recognizing the condition as a public
health priority and called member states to respond with
a comprehensive approach to prevention and control
[36]. The 2012 World Global Alliance survey showed
that, out of 46 African countries invited, only twelve
responded, and just two of these had national strategic
documents on the prevention and control of viral hepa-
titis. Ethiopia was one of the countries that did not re-
spond to this survey request [34]. Similarly, only 18
African countries responded to the 2014 World Alliance
Civic Society survey [37].
A lack of hepatitis data is a global challenge not just
limited to Africa. Most estimates used in articulating
policies and strategies come from systematic reviews and
statistical modeling. In Ethiopia, viral hepatitis is not in-
cluded in the Integrated Disease Surveillance Response
(IDSR) system, and a lack of periodic surveys contributes
to the paucity of data. For instance, a national hepatitis
B survey was conducted in Ethiopia three decades ago
[13], and there has not been any nationwide survey on
hepatitis C. Thus a few small-scale regional studies have
been used to estimate the magnitude of the problem.
Such studies clearly require careful interpretation to be
used as a representative data for the whole country. Glo-
bally, the silent chronicity of the infection and a lack of
adequate and timely data for clinical decision-making
has contributed to the infection being neglected in the
global public health agenda. The lack of data has af-
fected viral hepatitis to the extent that it was not
included in the Millennium Development Goals despite
the huge disease burden. It is unfortunate deaths from
the condition have increased by 50 % over the period
covered by the MDGs [38]. Stephen Locarnini, director
of the WHO Regional Reference Laboratory for Hepa-
titis B, expressed this mishap as “an epidemiological
oversight based on flawed data." Furthermore, Charles
Gore, President of the World Hepatitis Alliance, empha-
sized the continued lack of attention to the infections by
stating that “the failure is compounded by not including
viral hepatitis in the post 2015 sustainable development
agenda” [38]. This neglect of hepatitis prevention, care,
and treatment by the global community has negatively
influenced developing nations like Ethiopia, and it is not
surprising if such countries lack a coherent policy and
strategy for a national response.
Data collection, analysis, and dissemination framework
are prerequisites for informing policy and strategy in
prevention and control efforts. Strengthening the sur-
veillance system through a national cancer registry is
also another step that could help quantify the scale and
distribution of the disease and to measure and gauge
prevention and control efforts. The FMOH Health Sec-
tor Development Plan (HSDP IV) in which little em-
phasis was given to viral hepatitis as a public health
agenda is due to end in 2015. The upcoming plan
(2016–2020) must provide strategic guidance on hepa-
titis in line with current global thinking.
Prevention of transmission
Prevention of transmission primarily starts with behav-
ioral change on safer sex. Beyond that, it includes insti-
tutional interventions that focus on prevention of
mother to child transmission, safe blood transfusion,
vaccination, and safe and rational injection practices and
appropriate medical waste management.
Prevention of mother to child transmission
In sub-Saharan Africa, over 90 % of children with hepa-
titis B are infected early in life through vertical and early
neonatal transmission from their mothers. In Ethiopia,
the prevalence of hepatitis B in pregnant women is esti-
mated to be around 3.7 % [39], and there is no screening
protocol for these mothers during their antenatal visits.
Countries like Cameroon, Mauritania, and Rwanda suc-
ceeded in developing national guidelines to prevent
mother to child transmission of chronic hepatitis [40].
As a measure to improve maternal and child health, the
Chinese initiative of integrating HIV, syphilis, and hepa-
titis B screening into antenatal care has been shown to
be a cost-effective strategy [41]. However, universal
screening for hepatitis C is not recommended [42] be-
cause of the low prevalence of hepatitis C, minimal risk
of Mother To Child Transmission (MTCT), and a lack
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of cost-effective interventions to minimize the risk of
transmission [43].
Blood screening
Interviews with national and regional blood bank labora-
tory technologists showed that screening for HIV, hepa-
titis B and C, and syphilis is routine as outlined in the
blood bank standard operating procedure. The infor-
mants confirmed that the tests are serological and not
molecular; thus, there is a risk of recent infection trans-
mission in the window period. However, routine blood
collection practice is from voluntary, non-remunerated
donors, and blood collection from paid or replacement
donors is not recommended by the standard to decrease
the window-period risk.
Universal screening of blood and blood products be-
fore transfusion has long been a challenge in many
countries due to several issues, including test kit short-
age. Since 2001, the World Health Organization has
been working in collaboration with PEPFAR and Center
for Disease Control (CDC) to improve the availability,
adequacy and safety of blood in Ethiopia. The country
formulated blood transfusion strategy in February 2005.
The strategy included the screening of blood and blood
products for transfusion-transmissible diseases with par-
ticular emphasis on HIV, hepatitis B and C, and syphilis.
A few prevalence studies from Ethiopia have addressed
blood donors. Blood donor screening in two regions of
Ethiopia showed a 6.2 % prevalence of HBsAg and a 1 %
prevalence of anti-hepatitis C infection markers [44].
Other similar regional studies showed a prevalence of
hepatitis B in blood donors to be as high as 14.1 %,
highlighting the need to strengthen hepatitis B and C
screening practices among blood donors through regular
quality control procedures.
Vaccination
According to the key informant from FMOH, Ethiopian
hepatitis B prevention strategy, provided as a component
of a pentavalent vaccine, has been in place since 2007.
The activity was said to be supported by the Global Alli-
ance for Vaccines and Immunization (GAVI). The partici-
pant also highlighted that the ministry had actively tried
to implement a program for screening health care staff
and providing them the monovalent hepatitis B vaccine,
although with limited success due to budget constraints.
One of the greatest achievements in the prevention of
hepatitis was the development of the hepatitis B vaccine
in 1982. The vaccine is safe and 95 % effective against all
genotypes [45]. Since 1991, the WHO has recommended
universal hepatitis vaccination of children and high-risk
groups to reduce new infections and minimize the pro-
gression to cirrhosis and hepatocellular carcinoma. The
primary objective of vaccination is to reduce the disease
burden of chronic hepatitis B infection and reduce
deaths from liver cirrhosis and liver cancer. Globally,
three different strategies are used to implement hepatitis
B vaccination:
i. Prevention of perinatal infections via a 24-h-birth-dose
vaccination; Routine childhood vaccination integrated
as the pentavalent vaccine in the Expanded Program
on Immunization;
ii. Catch-up vaccination in adolescents and high-risk
groups.
24-hr.-birth-dose vaccination
Universal administration of hepatitis B vaccine at birth
is not yet implemented in Ethiopia. In fact, only 10 % of
newborns in Africa get the vaccine [46]. The World
Health Organization recommends the birth dose of vac-
cination to be given in the first 24 h to prevent vertical
and early neonatal transmissions. Therefore, introducing
and scale-up of the birth dose in Ethiopia is critical as it
prevents prenatal and early-childhood infections, which
are the most common modes of transmission and have a
90 % rate of progression to liver cirrhosis and hepatocel-
lular carcinoma. However, implementation of the vac-
cine requires routine screening of pregnant women,
timely administration by skilled personnel, and certain
medical technologies. These are some of the potential
challenges which require careful planning and resource
mobilization [47]. The other challenge is the possibility
that GAVI’s support may not be available to Ethiopia as
GAVI stopped its support for the monovalent hepatitis
vaccine since December 2005 due to issues of cost ef-
fectiveness [48].
Pentavalent childhood immunization
In Ethiopia, the pentavalent vaccine has been introduced
since 2007, and within 7 years, a coverage of 84 % is re-
ported [49]. The vaccine contains hepatitis B vaccine
along with Diphtheria, Pertussis, Tetanus (DPT) and Hae-
mophilus influenza B and is given at 6, 10, and 14 weeks
of age in the Expanded Program on Immunization. The
GAVI-funded primary preventive intervention through
immunization is reported to reduce vaccine-preventable
disease burden by over 80 %. Globally, the coverage of
three-dose hepatitis B infant vaccination has reached 82 %
[50], and countries are expected to achieve a coverage of
≥90 % nationally and ≥80 % in every district by 2020 [51].
Monovalent hepatitis B vaccine
The World Health Organization recommends monova-
lent hepatitis B vaccination as a catch-up strategy in low
and intermediate endemic countries [52]. In high burden
countries like Ethiopia, it is expected that large-scale
routine vaccination of infants reduces transmission. Even
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so, high-risk groups like healthcare professionals and
waste handlers can benefit from this vaccination. How-
ever, the monovalent vaccine is currently expensive and
inaccessible for the majority of those who need it. Thus,
the government must encourage generic low-cost hepa-
titis B vaccination in the community as a family-based
self-care approach.
Regarding vaccination for hepatitis C, the current avail-
ability of new second-generation Directly Acting Antivi-
rals (DAAs), sofosbuvir, simeprevir, and their over 90 %
cure rate for hepatitis C [46] is expected to underestimate
the need for vaccination. However, issues of drug resist-
ance, suboptimal efficacy for different genotypes, the high
cost, and side effects justify the need for developing hepa-
titis C vaccine. Currently, the vaccine trial has reached the
testing stage on an animal model which shows promise,
and it is a public health priority [50].
Safe and rational injection practices and medical waste
management
The key informant from FMOH believed the low preva-
lence of hepatitis C, especially in the post-HIV era,
might be due to improved infection-control procedures
in the health institutions and blood banks. Besides, in-
fection prevention is incorporated into the pre-service
training curricula of medical studies. This too, is ex-
pected to impact the incidence of viral hepatitis. There
is, however, no documented evidence of what the inter-
ventions achieved so far in the country.
One of the positive spinoffs of the HIV epidemic on
the health systems of developing countries like Ethiopia
is improvements in infection prevention activities. How-
ever, a lot of work remains to be done in the area. A sur-
vey conducted in four regions of Ethiopia showed that
68 % of health facilities used inappropriate sharp waste
disposal methods, and just 2 % of healthcare workers
practiced appropriate recapping of needles [32]. In a
knowledge assessment survey of health professionals
about infections transmitted by needle-stick injuries,
98 % mentioned HIV while 75 % identified hepatitis B,
and only 28 % mentioned hepatitis C. Similar study on
waste handlers showed 95 % of them knew that needle
or sharp materials prick can transmit infections. Cur-
rently, hepatitis B vaccination rate among healthcare
professionals is 7 % [32]. A study in Addis Ababa on
medical waste handlers showed that hepatitis B and C
infections are more common among the handlers than
non-handlers and, despite this, none of them received
the hepatitis B vaccination [53]. A study from the North-
ern part of Ethiopia assessed the general infection pre-
vention practice in a health care setting revealed that
knowledge on infection prevention is around 84.5 %
while only 54.5 % of the respondents had safe infection
prevention practices [54]. Findings from these studies
showed that despite enhanced knowledge of healthcare
workers and waste handlers on the risk of infection from
unsafe injections and improper medical waste handling,
their actual practice is suboptimal. Therefore, the need
to design and implement adequate preventive measures,
including hepatitis B vaccination, and creating safe
working environment should be emphasized.
Screening, care, and treatment
In viral hepatitis infection, there are three main categor-
ies of cases: acute infection, chronic carriers and those
presenting with complications. Early case detection,
treatment, and care help prevent progression to serious
complications, prevent premature deaths, increase prod-
uctivity and reduce medical costs.
Screening
All in all, screening practice seems suboptimal in
Ethiopia. One of the interviewees was a 40-year-old edu-
cated man working as a section head in a government
office. When asked about the circumstances of his diag-
nosis, he replied: “I did not know that I had hepatitis B
until I was screened to go abroad for a short training
course.” He had a history of gastrectomy with blood
transfusion in the early 80’s. Sadly, the health facility
never gave him any further information, and he only be-
came aware of the consequences and safety precautions
when searching the web. He expressed his concern
about the lack of routine screening practices by stating,
“I feel sad when I think about so many people like me
who did not get the chance to be screened. And also those
with the virus who are unaware of their status, and thus
cannot protect their sexual partners.” He appeared to
have benefited from the screening as, after learning of
his infection, his wife and two daughters were screened,
found to be negative and obtain the catch-up hepatitis B
immunization.
This case scenario and other interviews with clients
showed that community awareness about hepatitis B and
C infections in Ethiopia is very low, and that infections
are commonly transmitted unknowingly. In Ethiopia, very
few people have the opportunity to know their hepatitis
infection status. Typically, people get tested either during
pre-employment medical checkups, as a requirement for
immigration, or during blood donation. The testing rate in
Ethiopia is estimated to be about 10–15 % for HBV and
5–10 % for HCV [55]. According to WHO and World
Hepatitis Alliance data, two-thirds of the world popula-
tions live in countries where there is no access to hepatitis
testing [34]. Conducting mass screening for hepatitis B
and hepatitis C might not be needed in Ethiopia given the
high number of competing priorities and the large popula-
tion size. However, targeted screening of high-risk groups
such as health-care workers, medical waste handlers,
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commercial sex workers, people living with HIV, close
contacts of hepatitis B and hepatitis C infected individuals,
and hemodialysis patients can help prevent viral hepatitis
in the most exposed.
Care and treatment
Physicians in private and government hospitals are fre-
quently confronted with chronic viral hepatitis cases,
including asymptomatic carriers and those with compli-
cations. Such individuals are usually identified during
screening of clients for different purposes, after patients
presented with complaints pointing towards liver prob-
lems, or as part of routine laboratory workups. All the
interviewed health workers highlighted that they had a
professional duty to treat hepatitis B and C patients
based on current guidelines and recommendations by
recent scientific evidence. However, they cited the lack
of treatment guidelines and screening strategy and the
unavailability and high cost of therapy as the major
challenges to providing the necessary care to their pa-
tients. The frustration of health workers is evident in
what one of the internists mentioned: “I remember my
clinical practice in the 90s when there were no anti-
retroviral drugs to treat HIV cases, and a similar sce-
nario has happened to chronic viral hepatitis patients. I
feel desperate because I am unable to help my patients
with scientifically recommended modalities.”
In recent years, advances in medicine have placed us in
an era in which we can control hepatitis B and cure hepa-
titis C. A variety of drugs are currently available for the
treatment of hepatitis B. These include Interferon alfa,
PEGylated Interferon alfa, Entecavir, Tenofovir, and
Adefovir [56]. Lamivudine is also used in many
resource-poor settings because of its low cost, toler-
ance, and safety. Although its use as a single agent is
diminishing due to the high rate of drug resistance,
lamivudine still has a role in combination with Tenofo-
vir in those who are co-infected with HIV [57].
For years, the standard treatment of hepatitis C infec-
tions has been a combination of Interferon and Ribavirin.
This treatment protocol, given weekly, has a response
rate of 40–50 %. A better response rate of 65–75 %
was achieved with the arrival of DAAs Telaprevir and
Boceprevir in 2011. The rates are even higher (>90 %)
when these drugs are used in combination with the new
second generation DAAs Sofosbuvir and Simeprevir. The
second generation antivirals act against all genotypes of
HCV, have fewer adverse effects and are used as a single
pill dose treatment over a short course of 2–3 months [45].
Despite these promising advances in the treatment of
viral hepatitis, several challenges remain. Access to these
treatments and availability of systems for screening and
virological monitoring remains low in many resource-
poor countries like Ethiopia. Besides, treatment and
accompanying laboratory tests are very expensive. In
Ethiopia, for instance, the diagnostic package, including
routine liver function tests costs between 220 and 425
USD, and drugs like Interferon cost as much as 7200
USD for a 6-month treatment. Furthermore, the services
are limited to specialized clinics, which are very few and
are found only in the capital.
Interviews with pharmacists working in private and
government institutions confirmed that physicians com-
monly prescribe Interferon, Entecavir, and Tenofovir for
chronic hepatitis B. These drugs are not available in any
drug stores and pharmacies across the country. How-
ever, a few stores took orders from clients and obtained
the drugs from abroad. Pharmacists interviewed from
public sector told us that they had Lamivudine and
Tenofovir on their shelves, but these drugs are only used
for HIV-infected individuals free of charge. In addition,
the authors visited ten pharmacies at different corners of
the capital Addis Ababa to check the availability of anti-
virals used for the treatment of hepatitis B and the
DAAs. None of the visited pharmacies had these medi-
cines and vendors in most of the pharmacies were not
familiar with DAAs.
Inability to use antiretrovirals for the treatment of
hepatitis B is another aspect of the drug availability chal-
lenge. The experience of one of the authors clearly
shows this problem and the frustration of patients who
are aware of possible benefits from such drugs. The au-
thor witnessed a 32-year-old man who had hepatitis B
and tried to get specific antiretrovirals from a hospital
dispensary being labeled “dishonest” by a physician
working in an NGO working mainly on HIV/AIDS. The
doctor boldly stated, “this man is trying to deceive us
and get treatment from the HIV/AIDS drugs funded by
PEPFAR.” In this case scenario, the patient didn’t know
the funding arrangements or the politics of HIV funding.
He knew he could benefit from the use of such drugs
and was genuinely attempting to get. This patient being
considered a deceiver is appalling. Besides, irrespective
of the funding arrangements, this kind of marginalizing
attitude by health care professionals, the system as well
by donor programs is unethical and raises human right
and equity issues in health. This is also what one of the
interviewed health workers discussed “I know that chronic
viral hepatitis, especially hepatitis B does not have a cure
just like HIV, but current treatment modality prolongs the
development of complications and gives an improved qual-
ity of life. I am curious that why programs and donors are
not interested in combating viral hepatitis.”
The Ethiopian Food, Medicines, and Health Care Ad-
ministration and Control Authority (FMHACA) is re-
sponsible for regulating health care practice, premises,
and health care products. According to the key inform-
ant from the authority, antiviral drugs like Lamivudine
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and Tenofovir are found in the national essential drug list
for use in HIV/AIDS treatment only. Moreover, drugs like
Entecavir are yet to be included on the list. The reason he
gave for prohibiting the utilization of these medicines for
hepatitis B patients is fear of misuse and the possible
emergence of drug resistance. Donors also fund the drugs
with an explicit agreement that they are strictly used for
HIV program. However, the interviewee recognized the
need to register effective antiviral drugs used for the treat-
ment of viral hepatitis. As he said, the main challenge is a
lack of policy and guidance from the Ministry of Health to
support the process of including those medications in the
essential drug list to be available outside HIV program
context. Hence, the authority is currently providing on-
demand temporary permissions through the drug registra-
tion department for individuals who bring prescription
and few drug importers upon request. We confirmed this
fact through our interview with respondents from drug
importing company. As one of the participants stated, im-
porters often get temporary need-based permission to im-
port antiviral medicines for chronic viral hepatitis, and
that they are not allowed to import such drugs in bulk.
The informant also admitted that, as a business person, he
was not interested in doing so, as the drugs are extremely
expensive, and the turnover is very low.
Local governments, international donors, civic soci-
eties, and the pharmaceutical industries must work in
partnership with the government to mobilize resources
to ensure accessibility of low-cost generic antiviral drugs
in low-income countries like Ethiopia. Alongside devel-
oping policy and strategies, and updating essential drug
lists, the Ethiopian government should also work on
identifying platforms for providing comprehensive ser-
vices for viral hepatitis in an integrated way. In a country
like Ethiopia, it is not usually possible to provide high-
quality holistic specialty care throughout the country.
However, the success achieved through an innovative
Health Extension Program since 2003 at the primary
health care level, made health care to reach the majority
of the rural population. Thus, incorporating hepatitis ac-
tivities in this institutional framework could facilitate
meaningful gains in the coverage of such services. The
possibility of integration with HIV prevention, care and
treatment services is also one area for consideration.
Given the similarities in mode of transmission, disease
progress, some shared antiviral drugs, and the 5–20 %
co-infection rate of HIV with either hepatitis B or C,
using the HIV program platforms for a viral hepatitis re-
sponse might prove cost effective. This allows sharing
resources and helps avoid duplication of efforts from a
health system strengthening standpoint. Some lessons
from HIV treatment, such as the noble task shifting ap-
proach, can also inform future viral hepatitis care in
rural Ethiopia.
In this study, we tried to show the existing challenges
to the national viral hepatitis response in Ethiopia and
highlighted gaps for policy and strategy attention. The
study might have benefited more if there was some
quantitative validation of the qualitative evidence pre-
sented here.
Conclusions
Viral hepatitis and its disease burden are getting little at-
tention in Ethiopia and many low-income countries. The
levels of technical guidance and financial support from
the international community are low. There is, however,
a global momentum which is driving improvement in
viral hepatitis response worldwide. To date, the response
to the infections in Ethiopia is patchy, and the country
lacks tools and systems necessary for an effective re-
sponse at all levels. Thus, the country needs to formulate
policy and strategies in the areas of disease surveillance,
risk group identification and screening, implementation
of the birth dose of hepatitis B vaccine, and care and
treatment. Improving availability of data on viral hepa-
titis, access to low-cost generic drugs and developing
treatment guidelines are also critical. Leveraging the suc-
cessful Health Extension Program for a hepatitis re-
sponse, and exploring ways to learn from and integrate
into the HIV/AIDS program could facilitate the sharing
of resources and help improve cost-effectiveness. Above
all, providing care and treatment for people infected
with viral hepatitis is a moral, ethical, and human rights
issue that needs to be addressed promptly.
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